Riverhead Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Riverhead Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-61	Closed	-$56K	–	1549
2019 Q2	$56K	Buy	61 +14	+30%	+$17.2K	﹤0.01%	1441
2019 Q1	$74K	Hold	47	–	–	﹤0.01%	1386
2018 Q4	$87K	Hold	47	–	–	﹤0.01%	1334
2018 Q3	$110K	Hold	47	–	–	﹤0.01%	1375
2018 Q2	$160K	Hold	47	–	–	0.01%	1198
2018 Q1	$132K	Hold	47	–	–	0.01%	1247
2017 Q4	$120K	Buy	47 +16	+52%	+$45.5K	0.01%	1280
2017 Q3	$87K	Buy	31 +7	+29%	+$18.4K	﹤0.01%	1318
2017 Q2	$57K	Buy	24 +11	+85%	+$21.8K	﹤0.01%	1386
2017 Q1	$31K	Hold	13	–	–	﹤0.01%	1391
2016 Q4	$28K	Hold	13	–	–	﹤0.01%	1373
2016 Q3	$31K	Sell	13 -9	-41%	-$26.9K	﹤0.01%	1309
2016 Q2	$58K	Sell	22 -37	-63%	-$120K	﹤0.01%	1296
2016 Q1	$187K	Sell	59 -19	-24%	-$78.9K	﹤0.01%	1274
2015 Q4	$402K	Buy	78 +48	+160%	+$210K	0.01%	995
2015 Q3	$95K	Buy	+30	New	+$116K	﹤0.01%	1121

Other funds holding ACOR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Riverhead Capital Management's ACOR Position: Q3 2019 in Review

Riverhead Capital Management sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 61 shares — an estimated $56K sold.

Riverhead Capital Management first reported a position in ACOR in Q3 2015 and held it in 16 quarters. The position peaked at $402K in Q4 2015. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

Riverhead Capital Management reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
Riverhead Capital Management sold 61 Acorda Therapeutics shares in Q3 2019, an estimated $56K.
Riverhead Capital Management first reported a position in Acorda Therapeutics in Q3 2015 and held it in 16 quarters.
Riverhead Capital Management's Acorda Therapeutics position peaked at $402K in Q4 2015.
151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on Riverhead Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.